Apoptotic Cell Clearance and Its Role in the Origin and Resolution of Chronic Inflammation by Luis Enrique MuÃ±oz et al.
EDITORIAL
published: 25 March 2015
doi: 10.3389/fimmu.2015.00139
Apoptotic cell clearance and its role in the origin and
resolution of chronic inflammation
Luis Enrique Muñoz 1*, Christian Berens2, Kirsten Lauber 3, Udo S. Gaipl 4 and Martin Herrmann1
1 Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany
2 Institute of Molecular Pathogenesis, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Jena, Germany
3 Department of Radiation Oncology, Ludwig-Maximilians-University Munich, Munich, Germany
4 Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany
*Correspondence: luis.munoz@uk-erlangen.de
Edited and reviewed by:
Pietro Ghezzi, Brighton and Sussex Medical School, UK
Keywords: clearance, cell death, phagocytosis, chronic, inflammation, cancer, atherosclerosis, autoimmunity
During normal tissue turnover, innate immune sentinels swiftly
clear dying cells in an immunologically silent manner. Large
amounts of nuclear chromatin are meticulously kept away from
the immune system to prevent inflammation and, eventually,
autoimmunity from developing. In case this highly efficient sur-
veillance system is derailed, the unanticipated presence of post-
mortem remnants in tissues can challenge the otherwise nor-
mally ensuing immunological tolerance. Apoptotic cell death is
the most natural way to preserve this precious tissue homeosta-
sis. Early recognition and swift clearance of cells undergoing
apoptosis ensures the prevention of tissue damage and autoim-
mune reactions (1). Kimani et al. thoroughly review in this
Research Topic, the most recent evidence linking autoimmune
diseases and the recognition of apoptotic cells via surface-exposed
phosphatidylserine (2).
Besides the autoimmune phenotype of chronic inflammatory
rheumatoid disorders, a plethora of pathologies have been asso-
ciated with defects in genes involved in the clearance of cell
remnants from tissues (3, 4). This Research Topic bundles a set
of manuscripts describing various ways of how such “uncleared”
cell remnants participate in the pathogenesis of chronic inflam-
matory diseases and also cancer. Improving our knowledge of
the immune modulatory language(s) spoken by dying and dead
cells and their constituents may prove essential for understand-
ing the key processes involved. Ultimately and hopefully, this
may lead to the development of new classes of therapeutic and
disease-modifying agents (5).
For example, González and Hidalgo emphasize that it is now
possible to take advantage of the huge amount of published evi-
dence on therapeutic modulation of the liver X receptor activity in
clearance-associated diseases (6). Notably, pharmacological regu-
lation of such nuclear factors, which are activated upon recog-
nition of dying cells, may enhance the ability of macrophages to
clear dead cells and thereby provide additional beneficial effects for
treating clearance-related diseases like osteoporosis, rheumatoid
arthritis, atherosclerosis, diabetes, and Alzheimer’s disease (7–10).
Upon recruitment to sites of acute inflammation, neutrophils
respond either with phagocytosis of the inflammatory trigger,
degranulation, or with the formation of neutrophil-extracellular-
traps (NETs) (11) exposing modified chromatin at the site of
the initial injury (12). The nature of this material implies the
massive death of neutrophils, and this response is important for
both the inactivation of the aggressor and the resolution of the
initial inflammation (13). However, how this battlefield is finally
cleaned up and cleared has not been studied yet and may surely
provide new therapeutic options for autoimmune diseases (12,
14). Intense current research on the immunobiology of this spe-
cial way of dying called NETosis also promises new therapeutic
targets for ameliorating autoinflammation (15, 16). Severe and
standard treatment resistant forms of pulmonary inflammation
may also profit by novel dual interventions targeting both cell sur-
vival and promotion of apoptotic cell clearance by phagocytes as
Felton et al. and Szondy et al. summarize in this issue (17, 18).
Although one of the multiple mechanisms of action of glucocorti-
coids is to enhance apoptotic cell clearance by macrophages (19),
their long-term use has many side effects that strongly burden
chronically diseased patients leading to higher rates of morbidity.
Alternatives to classic therapies and specific pathogenesis-targeted
therapies are therefore very much welcome.
The many different signals expressed or secreted by apop-
totic cells noticeably determine the reaction of the organism
to the event triggering death. Any shortcomings in phagocytic
clearance, either by impaired clearance, excessive death or any
other reason, are invariably related to continuous stimulation
of the organism by either pro-inflammatory/destructive or anti-
inflammatory/healing signaling. Many chronic inflammatory dis-
eases are driven and somehow modulated by metabolites released
from dying cells. For example, Chen et al. present an overview of
the various sites of action of nucleotides in inflammatory condi-
tions (20). Intervention at this level may shift the balance toward
anti-inflammation, thereby achieving the therapeutic goal more
effectively.
In the case of solid tumors, the metabolites and, especially, the
danger signals released may serve as biomarkers. Gehrmann et al.
nicely demonstrate in this Research Topic that stress response pro-
teins are released already by premalignant conditions of the liver as
well as by hepatocellular carcinoma (21). This can be important for
prognosis, prediction, and monitoring. The tumor microenviron-
ment, especially directly after anti-cancer treatment, is overflowing
with mediators and signals from dead and dying cells. To obtain
an efficient anti-tumor immune response, an immune-suppressive
microenvironment has to be shifted to an activating one. The
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latter might be achieved by rendering the tumor cells immuno-
genic, namely, by inducing immunogenic tumor cell death forms
by standard treatments such as radio- and/or chemotherapy (22).
Furthermore, short range danger signals foster leukocyte infiltra-
tion into the tumor and initiate an inflammatory response, which
is afterwards supplanted by long-range healing and regenerative
signals, which then, in contrast, may support tumor proliferation.
The review from Willems summarizes evidence documenting the
dark side of apoptosis in modulating anti-tumor responses (23).
A delicate balance exists between anti-tumor reactions and coun-
teracting immune suppression. In this scenario, the role of tumor
associated macrophages as sensors and central orchestrators of
tumor-promoting reparatory and anti-inflammatory signals has
recently been highlighted by Ford et al. (24). In addition, avoid-
ing tumor repopulation after anti-cancer therapy by considering
the immune-suppressive consequences of apoptotic cell clearance
should be taken into account as a cautionary premise for each
and every anti-cancer treatment (25–28). Of note, inflamma-
tory reactions, DNA damage responses, and cell death forms are
highly interconnected (29). Alterations in the clearance of dying
and dead cells, their remnants, and their constituents that leak
out after membrane rupture are therefore central elements in all
inflammatory conditions, starting from its origin and ending in
its resolution.
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